Cardiac resynchronization therapy market is projected to amass significant traction owing to the increasing incidence of heart failures. Cardiac resynchronization therapy is a treatment that helps the heart beat at the right rhythm. It uses a pacemaker to reinstate the usual timing pattern of the heartbeat. The pacemaker coordinates the timing of the upper heart chambers as well as lower heart chambers. The CRT works on the timing between both the right and left sides of the heart.

The cardiac resynchronization therapy system is made up of two parts, one being the heart device. The heart device comprises of a small computer along with a battery in a small titanium metal case usually the size of a pocket watch. The second part is insulated wires referred as leads which can be implanted to carry electrical impulses to the heart. The benefits associated with this therapy are increase in blood flow and improvement in heart's efficiency.

The CRT devices are cardiac EP (electrophysiology) systems which include a small electronic device that is implanted surgically into a pocket of skin to help contract both heart ventricles together. These are also known as biventricular pacemakers and are used for pacing or include a built-in defibrillator.

The cardiac resynchronization therapy market is bifurcated in terms of product, age, end-use, and regional landscape.

Based on product, the market is bifurcated into CRT-P and CRT-D. Among these, the CRT-P segment was valued at around $380 million in 2019 and is expected to register substantial growth in the ensuing years. The procedure for implantation of CRT-P is simple and it lasts for two to four hours. The intervention is performed usually by local anesthesia and at times under short-term sedation.

The functioning of CRT-P also tends to deliver small electrical impulses to the left as well as right ventricles to help them contract with the heart pumping efficiently. Through the help of pacemakers, heart patients can maintain a healthy as well as normal heart rhythm, helping the body circulate the amount of blood it needs.

With respect to age, the market is segmented into below 44 years, 45-64 years, 65-84 years, and above 85 years. Among these the below 44 years segment is projected to witness fastest growth at 7.1% over the analysis period.

Based on end-use, the market is classified into hospitals, cardiac care centers, and ambulatory surgical centers. Among these, the hospitals end-use segment was valued at around $950 million in 2019 and will show appreciative growth. The growing number of medical applications has created a larger frequency of patients with complicated devices that require follow up care from cardiologists, electro-physiologists, heart failure specialists, and general practitioners.

From a regional frame of reference, the Latin America CRT devices market was valued at around $60 million in 2019 and will further witness robust growth. MEA CRT devices market was valued at around $45 million in 2019 and is set to gain significant traction throughout the forecast timeline.